The development of biological disease-modifying antirheumatic drugs (DMARDs), including anti-TNF, anti-IL-1 and anti-IL-6 antibodies, have contributed to ameliorating patients’ disease status and delaying the RA progression (Brzustewicz and Bryl, 2015). Here, IL1B is linked to rheumatoid arthritis.